Treats Moderate. Sold as Prempro, Premphase, Premphase 14/14. Every FDA application for this active ingredient. Boxed warning
As of Nov 22, 2026, FDA lists 2 applications for Estrogens, conjugated; Medroxyprogesterone acetate (sold as Prempro, Premphase, Premphase 14/14), first approved Dec 30, 1994, with 4 new uses approved and 0 published complete response letters.
| Dec 30, 1994 | Prempro, PremphaseNDA 20303 · New combination | Wyeth Pharmaceuticals | 6 | Discontinued |
| Nov 17, 1995 | Prempro, Premphase 14/14NDA 20527 · New dosage form | Wyeth Pharmaceuticals | 39 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA